DK1572087T3 - Antistoffer med cancerantigen TMEFF2 og anvendelser deraf - Google Patents

Antistoffer med cancerantigen TMEFF2 og anvendelser deraf

Info

Publication number
DK1572087T3
DK1572087T3 DK03744243T DK03744243T DK1572087T3 DK 1572087 T3 DK1572087 T3 DK 1572087T3 DK 03744243 T DK03744243 T DK 03744243T DK 03744243 T DK03744243 T DK 03744243T DK 1572087 T3 DK1572087 T3 DK 1572087T3
Authority
DK
Denmark
Prior art keywords
antibodies
applications
cancer antigen
tmeff2
antigen tmeff2
Prior art date
Application number
DK03744243T
Other languages
English (en)
Inventor
La Calle Agustin De
Ingrid Caras
Vinay Bhaskar
Debbie Law
Vanitha Ramakrishnan
Richard Murray
Daniel Afar
David Powers
Original Assignee
Pdl Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pdl Biopharma Inc filed Critical Pdl Biopharma Inc
Application granted granted Critical
Publication of DK1572087T3 publication Critical patent/DK1572087T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Toxicology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK03744243T 2002-03-08 2003-03-07 Antistoffer med cancerantigen TMEFF2 og anvendelser deraf DK1572087T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36283702P 2002-03-08 2002-03-08
US43681202P 2002-12-27 2002-12-27
PCT/US2003/007209 WO2003075855A2 (en) 2002-03-08 2003-03-07 Antibodies against cancer antigen tmeff2 and uses thereof

Publications (1)

Publication Number Publication Date
DK1572087T3 true DK1572087T3 (da) 2008-08-25

Family

ID=27807977

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03744243T DK1572087T3 (da) 2002-03-08 2003-03-07 Antistoffer med cancerantigen TMEFF2 og anvendelser deraf

Country Status (15)

Country Link
US (5) US7288248B2 (da)
EP (1) EP1572087B1 (da)
JP (2) JP2006502092A (da)
KR (1) KR101104655B1 (da)
AT (1) ATE395082T1 (da)
AU (1) AU2003252830B2 (da)
CA (1) CA2478683C (da)
DE (1) DE60321041D1 (da)
DK (1) DK1572087T3 (da)
ES (1) ES2305481T3 (da)
IL (1) IL163902A0 (da)
PT (1) PT1572087E (da)
SI (1) SI1572087T1 (da)
WO (1) WO2003075855A2 (da)
ZA (1) ZA200407733B (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2357798T3 (es) * 1995-05-19 2011-04-29 Human Genome Sciences, Inc. Factor de crecimiento transformante alfa hii.
US20040141983A1 (en) * 1999-03-15 2004-07-22 Protein Design Labs, Inc. Compositions against cancer antigen LIV-1 and uses thereof
WO2003075855A2 (en) 2002-03-08 2003-09-18 Protein Design Labs, Inc. Antibodies against cancer antigen tmeff2 and uses thereof
US20030180348A1 (en) * 2002-03-22 2003-09-25 Levinson R. Saul Transcellular drug delivery system
ES2369542T3 (es) * 2002-07-31 2011-12-01 Seattle Genetics, Inc. Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
WO2004067564A2 (en) 2003-01-29 2004-08-12 Protein Design Labs, Inc. Compositions against cancer antigen liv-1 and uses thereof
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
US20050175619A1 (en) * 2004-02-05 2005-08-11 Robert Duffy Methods of producing antibody conjugates
NZ551180A (en) 2004-06-01 2009-10-30 Genentech Inc Antibody drug conjugates and methods
ES2547463T3 (es) 2005-06-17 2015-10-06 Merck Sharp & Dohme Corp. Moléculas de unión a ILT3 y usos de las mismas
WO2007002525A2 (en) * 2005-06-28 2007-01-04 Schering Aktiengesellschaft Tomoregulin antibodies and uses thereof
WO2008094176A2 (en) * 2006-06-19 2008-08-07 Tolerx, Inc. Ilt3 binding molecules and uses therefor
EP2121998A2 (en) * 2007-02-05 2009-11-25 Element Six (Production) (Pty) Ltd. Polycrystalline diamond (pcd) materials
PT2474557E (pt) 2007-07-16 2014-12-03 Genentech Inc Anticorpos e imunoconjugados anti-cd79b e métodos de utilização
PE20140625A1 (es) 2007-07-16 2014-05-29 Genentech Inc ANTICUERPOS ANTI-CD79b E INMUNOCONJUGADOS HUMANIZADOS
BRPI0818780A2 (pt) * 2007-10-19 2015-04-22 Genentech Inc Anticorpo anti-tenb2 planejados por cisteína e conjugados de medicamento com anticorpos
DK2657253T3 (da) 2008-01-31 2017-10-09 Genentech Inc Anti-CD79b-antistoffer og immunkonjugater og fremgangsmåder til anvendelse
PT2857527T (pt) * 2009-01-07 2019-02-19 Arcedi Biotech Aps Enriquecimento e identificação de células fetais no sangue materno e ligantes para tal utilização
US20110159588A1 (en) 2009-12-30 2011-06-30 Kui Lin Methods for Modulating a PDGF-AA Mediated Biological Response
PT3156420T (pt) 2010-12-06 2019-05-27 Seattle Genetics Inc Anticorpos humanizados a liv-1 e seu uso para tratar o cancro
US20150030602A1 (en) * 2011-12-23 2015-01-29 Phenoquest Ag Antibodies for the treatment and diagnosis of affective and anxiety disorders
CA2979671C (en) 2014-09-23 2020-03-10 Genentech, Inc. Methods of using anti-cd79b immunoconjugates
EA201891968A1 (ru) 2016-03-15 2019-02-28 Сиэтл Дженетикс, Инк. Комбинированное лечение с использованием liv1-adc и химиотерапевтического средства
EA202092849A1 (ru) 2018-05-24 2021-03-16 Янссен Байотек, Инк. Моноспецифические и мультиспецифические антитела к tmeff2 и их применение
ES2955791T3 (es) 2019-06-07 2023-12-07 Arcedi Biotech Aps Aislamiento de células fetales usando FACS
AU2022213825A1 (en) * 2021-01-27 2023-09-14 Janssen Biotech, Inc. Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003075855A2 (en) 2002-03-08 2003-09-18 Protein Design Labs, Inc. Antibodies against cancer antigen tmeff2 and uses thereof

Also Published As

Publication number Publication date
ES2305481T3 (es) 2008-11-01
WO2003075855A3 (en) 2006-03-23
US20080160012A1 (en) 2008-07-03
EP1572087A4 (en) 2006-11-02
WO2003075855A2 (en) 2003-09-18
US8257708B2 (en) 2012-09-04
JP2006502092A (ja) 2006-01-19
EP1572087B1 (en) 2008-05-14
SI1572087T1 (sl) 2008-10-31
US7674883B2 (en) 2010-03-09
DE60321041D1 (de) 2008-06-26
JP2011121950A (ja) 2011-06-23
US20080044840A1 (en) 2008-02-21
US7288248B2 (en) 2007-10-30
ZA200407733B (en) 2005-10-26
AU2003252830A1 (en) 2003-09-22
EP1572087A2 (en) 2005-09-14
KR20050002848A (ko) 2005-01-10
AU2003252830B2 (en) 2008-10-09
ATE395082T1 (de) 2008-05-15
US20080175846A1 (en) 2008-07-24
PT1572087E (pt) 2008-07-11
US20040096392A1 (en) 2004-05-20
US20110038864A1 (en) 2011-02-17
CA2478683C (en) 2016-01-26
KR101104655B1 (ko) 2012-01-13
JP5192537B2 (ja) 2013-05-08
US7785816B2 (en) 2010-08-31
IL163902A0 (en) 2005-12-18
US7824678B2 (en) 2010-11-02
CA2478683A1 (en) 2003-09-18

Similar Documents

Publication Publication Date Title
IL163902A0 (en) Antibodies against cancer antigen tmeff2 and uses thereof
CY1109741T1 (el) Sns-595 και μεθοδοι χρησης αυτου
CY1119291T1 (el) Πολυσθενη αντισωματα και χρησεις για αυτα
CY1120070T1 (el) Μεθοδοi θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος εναντι-erbb-μεϋτανσινοειδους
IL200404A (en) Conjugates of antibodies that bind 191p4d12(b)proteins and uses thereof for treating cancer
EP1844077A4 (en) DR5 ANTIBODIES AND THEIR USE
DK1784426T3 (da) Humaniserede anti-beta7-antagonister og anvendelser deraf
TW200510459A (en) RG1 antibodies and uses thereof
CY1112862T1 (el) Θραυσματα μονοσθενους αντισωματος χρησιμα ως θεραπευτικα
DK1383785T3 (da) Rekombinant tumorspecifikt antistof og anvendelse deraf
TNSN08255A1 (en) Anti-mn antibodies and methods of using same
CY1112055T1 (el) Συνθεσεις και μεθοδοι για την διαγνωση και θεραπευτικη αγωγη ογκου πνευμονα
NZ605429A (en) Therapeutic human anti-il-1r1 monoclonal antibody
PT1644484E (pt) Células autólogas de indução de auto-tolerância de origem monocítica e sua utilização em preparações farmacêuticas
CY1110759T1 (el) Παραλλαγες ανοσοσφαιρινων και χρησεις αυτων
BR0011838A (pt) Elementos misturadores estáticos empilhados
EA200701448A1 (ru) Специфически связывающаяся с крипто-антигеном человека молекула (варианты), композиция на ее основе (варианты), способ получения молекулы, способ лечения посредством молекулы (варианты) и способ ингибирования крипто-экспрессии в клетке больного
MX2009009926A (es) Anticuerpo tumor-especifico humano monoclonal.
ATE517340T1 (de) Sätze gegen kurze epitope gerichteter digitaler antikörper sowie diese verwendende verfahren
MXPA04006517A (es) Conjugados que comprenden un anticuerpo especifico para el dominio ed-b de fibronectina y sus usos para la deteccion y tratamiento de tumores.
DE602004027992D1 (de) In metastatischen menschlichen tumorzellen exprimiertes glycoproteinantigen sima135
ATE490785T1 (de) Parathormon-antikörper und damit zusammenhängende verfahren
DE60231971D1 (de) Ndet, und seine verwendung zur behandlung von krebs
ATE505538T1 (de) Dna-vektoren
CY1106200T1 (el) Αντισωματα εναντια σε κασπαση-8, παρασκευη και χρηση τους